← Leaderboards
Christopher Stuart Garris
Harvard Medical School
$210,717
Attributed
$210,717
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $64.6K · FY2015–21$100K$75K$50K$25K$0
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$210,717 · 2
By mechanism
F32$108,232 · 1
F31$102,485 · 1
Top collaborators
No co-investigators on record.
Most similar at Harvard Medical School
Same institution · by research overlap
- Allon Moshe Klein$7,807,178
Others in their field
Top investigators on “T-Lymphocyte”
- Barton F Haynes · Duke University$296,833,570
- Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
- Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
- Alessandro Sette · La Jolla Institute For Immunology$75,756,097
- Rama Rao Amara · Emory University$69,530,112
Research focus
T-LymphocyteSignal TransductionLeadPathway InteractionsPhenotypeSamplingImmune ActivationImmunotherapyMediatingMouse ModelExhaustCessation Of LifeRefractoryResponseCellsImmuneAntibodiesImmune SystemLigandsMalignant NeoplasmsCancer PatientCancer ImmunotherapyCell Surface ProteinsTreatment Efficacy
Grant awards (5)
CD40 agonism for the treatment of bladder cancer$43,678
F32 · FY2021 · CA · contact PI
CD40 agonism for the treatment of bladder cancer$64,554
F32 · FY2020 · CA · contact PI
The Role of Driver Mutations in Lung Cancer Response to Anti-PD-1 Therapy$31,579
F31 · FY2017 · CA · contact PI
The Role of Driver Mutations in Lung Cancer Response to Anti-PD-1 Therapy$35,681
F31 · FY2016 · CA · contact PI
The Role of Driver Mutations in Lung Cancer Response to Anti-PD-1 Therapy$35,225
F31 · FY2015 · CA · contact PI